# Agile Medical Device Software Development: Turning Regulatory Constraints Into Better Engineering Medical device software teams live with a contradiction that ordinary software companies rarely face. They are expected to move faster. They are also expected to prove, sometimes years later, exactly why a particular engineering decision was made. That changes almost everything. A feature request cannot simply travel from a product manager's backlog to production. Somewhere along that path, teams may need to consider patient risk, software safety classification, cybersecurity, verification evidence, configuration management, traceability, quality-system requirements, and regulatory documentation. Yet none of this makes iterative development impossible. In fact, the FDA recognizes AAMI TIR45:2023, which specifically addresses the use of Agile practices in medical device software development. The interesting question is therefore no longer whether Agile belongs in MedTech. It is what Agile becomes when failure has consequences beyond an unhappy customer. That is the challenge at the center of **agile medical device software development**: keeping the ability to learn and change without losing the evidence, discipline, and engineering controls required for a regulated product. ## Medical Devices Have a Speed Problem — but Not the Obvious One Software teams usually talk about speed in terms of release frequency. Weekly releases are better than monthly releases. Automated deployment is better than manual deployment. Two-week sprints sound more modern than a twelve-month development plan. That definition is too narrow for medical technology. A MedTech organization can write code extremely quickly and still take years to launch a product. Why? Because coding may not be the bottleneck. The bottleneck is often the time required to understand whether the software is actually ready. Requirements exist in one system. Risks live somewhere else. Verification evidence is maintained by another team. Architecture documentation is several versions behind the implementation. Cybersecurity has its own review process. Quality assurance discovers problems after engineering considers development finished. The code moves quickly. The organization does not. Agile becomes useful when it attacks this larger problem. ## The Real Product Is Software Plus Evidence There is a useful mental model for regulated development. A medical device software team is building two products simultaneously. The first is obvious: the software. The second is the body of evidence explaining that software. The two have to remain synchronized. Suppose developers modify how a monitoring application calculates a value used by a clinician. The updated algorithm may work perfectly from a purely technical perspective. But that is only one part of the story. The organization may also need to understand: * why the algorithm changed; * which requirement authorized the change; * whether the change affects a hazardous situation; * what risk controls apply; * which software components were modified; * how the behavior was verified; * which version contains the change; * whether new cybersecurity implications appeared. If those questions cannot be answered reliably, "working software" is not enough. This is one reason conventional interpretations of Agile sometimes struggle inside medical technology companies. The team optimizes the visible product while regulatory evidence becomes a parallel administrative project. The better model makes evidence part of development itself. ## Agile Is Not the Opposite of IEC 62304 A persistent assumption deserves to disappear: IEC 62304 does not require teams to use Waterfall. The standard establishes lifecycle activities and development disciplines rather than prescribing one specific development model. Industry guidance similarly notes that Waterfall, V-model, Agile, or Scrum are not mandated as the exclusive process. That matters because people sometimes confuse structured documentation with sequential development. They are not the same thing. You can have: **Structured requirements without freezing every requirement on day one.** You can have: **Formal verification without waiting until the final month of development.** You can have: **Risk management without performing one giant risk analysis after design is complete.** And you can have: **Traceability without maintaining a spreadsheet manually for eighteen months.** AAMI TIR45 exists precisely to address how Agile practices can operate within medical device software development and relevant regulatory expectations. The FDA currently recognizes the 2023 version of that guidance. The important word is *controlled*. Change is acceptable. Uncontrolled change is the problem. ## The Backlog Needs More Than Features A typical commercial software backlog contains things customers want. Medical device software needs a more complicated backlog. Some work will certainly be user-facing: "Allow clinicians to configure alert thresholds." "Display historical measurements." "Notify users when connectivity is interrupted." But other work may never appear in a product demo. A sprint may include: * implementing a risk-control measure; * updating software architecture; * verifying an interface; * evaluating a third-party dependency; * performing security testing; * resolving an anomaly; * improving test automation; * updating traceability; * documenting a design decision. None of these tasks should be treated as distractions from "real development." They are real development. This sounds obvious until deadlines become uncomfortable. Then documentation gets postponed, testing is compressed, risk work moves to another team, and the backlog quietly becomes a list of visible features. That is where compliance debt begins. ## Compliance Debt Behaves Like Technical Debt Most engineering leaders understand technical debt. Take enough shortcuts today and tomorrow's changes become harder. Compliance debt behaves similarly. Imagine a team completing 15 sprints while postponing documentation updates. Initially, nothing dramatic happens. Sprint velocity looks good. Features accumulate. Management sees progress. Then release preparation begins. Someone notices that 40 requirements changed. Several risk controls were modified. A collection of tests exists, but their connection to requirements is unclear. Architecture diagrams describe an earlier version of the product. Developers have to reconstruct why decisions were made months earlier. Suddenly, the organization spends six weeks "getting ready for compliance." Those six weeks were not created by regulation. They were created by delayed evidence. A healthier approach treats compliance work the way mature DevOps teams treat automated testing: something integrated continuously rather than performed as a cleanup operation. ## A Better Definition of Done The humble Definition of Done becomes surprisingly important in regulated Agile. For a normal mobile application, a team might define "done" as: Code completed. Code reviewed. Automated tests passed. Merged into the main branch. For medical device software, that definition can be dangerously incomplete. A more realistic Definition of Done might ask whether: * acceptance criteria have been satisfied; * required verification has been completed; * relevant risk controls have been evaluated; * traceability has been updated; * cybersecurity implications have been reviewed; * documentation reflects the implementation; * anomalies have been recorded; * configuration items are appropriately controlled. This does something important culturally. Quality stops being the responsibility of the department called Quality. It becomes a characteristic of completed engineering work. ## Risk Management Should Move at Engineering Speed Traditional risk-management processes sometimes operate on a different calendar from software development. Engineering works in two-week increments. Risk documents are reviewed quarterly. That gap is dangerous. Consider a connected medical device that introduces a new remote-control function. From a product perspective, it may be a straightforward feature. From a risk perspective, the feature could create questions about unauthorized access, network failures, delayed commands, incorrect states, data integrity, user errors, and cybersecurity threats. Waiting three months to consider those issues makes little sense. Risk analysis should happen close to the engineering decision. This is also one of the areas where iterative development can become an advantage. Agile-oriented medical device approaches can incorporate risk analysis and control activities into individual iterations rather than treating risk as a one-time exercise. The principle is simple: When the product changes, the understanding of its risks should change with it. ## Traceability Can Be Useful Instead of Painful Mention "traceability matrix" in the wrong engineering meeting and you can almost hear enthusiasm leave the room. There is a reason. Many teams have experienced traceability as clerical work. Copy requirement IDs. Update spreadsheets. Check columns. Repeat. But traceability itself is not the problem. Manual traceability is. Consider a requirement connected to a safety-related function. Ideally, the organization should be able to navigate something resembling: **User need → system requirement → software requirement → risk control → implementation → verification → result** Now suppose the software requirement changes. A strong system immediately makes the impact visible. Which tests need to run again? Which risk control is affected? Which component implements it? Which documentation needs review? Without traceability, people investigate manually. With good traceability, change becomes safer and faster. Paradoxically, the more Agile a regulated organization becomes, the more valuable strong traceability becomes. Iteration increases the frequency of change. Traceability reduces the cost of understanding that change. ## Architecture Cannot Be an Afterthought Agile's dislike of excessive upfront planning sometimes gets translated into a much more questionable idea: "Architecture will emerge." Some architecture certainly can. Safety-related architecture should not simply be left to chance. Medical device teams need enough early architectural understanding to reason about issues such as: * safety-critical components; * software interfaces; * hardware interactions; * data flows; * authentication; * external services; * failure modes; * third-party software; * connectivity; * update mechanisms. The goal is not to predict every class, database table, or API endpoint before implementation starts. It is to understand the boundaries where architectural decisions create significant risk. This leads to a more practical compromise: establish important architectural constraints early, then allow lower-level architecture to evolve through implementation and evidence. Agile architecture should be adaptive. It should not be accidental. ## Verification Becomes a Continuous Activity One of the strongest arguments for iterative medical device development is surprisingly traditional: Finding problems earlier is cheaper. Imagine discovering during final system testing that two foundational components behave incorrectly when connectivity disappears. Now imagine discovering the same problem during the sprint in which their interface was created. The technical defect is identical. The organizational cost is not. Continuous verification can include: * unit testing; * integration testing; * static analysis; * automated regression testing; * interface verification; * security testing; * build validation. The exact approach depends on the product, its safety implications, the quality system, and applicable regulatory requirements. But the strategic direction is clear. Do not build a mountain of unverified software and then attempt to prove that it works. Build evidence incrementally. ## Cybersecurity Makes Iteration More Important Connected medical devices face another uncomfortable reality. The threat environment does not freeze when the software requirements are approved. A dependency that appears safe today may disclose a vulnerability next month. An API may evolve. An authentication mechanism may prove inadequate. A new attack technique may expose an assumption that looked reasonable during architecture design. Medical device security standards recognized by FDA include risk-management-oriented approaches to device security, reinforcing the importance of treating cybersecurity as an ongoing engineering concern. Agile can help here because it gives teams a mechanism for incorporating new information. But once again, iteration alone is not enough. A security fix still needs controlled implementation. The change may need new tests. The risk analysis may need updating. Documentation may change. The resulting release needs to be identifiable. "Move fast" without traceability is not a cybersecurity strategy. ## The Sprint Is Not the Release This distinction clears up a surprising amount of confusion. A medical device organization can operate two-week development sprints without releasing a regulated product every two weeks. The two concepts are different. A sprint is an engineering cadence. A release is a controlled product event. Perhaps six sprints contribute functionality to one candidate release. During those sprints, developers repeatedly implement, review, test, and integrate smaller pieces of functionality. When the release candidate reaches the appropriate level of maturity, the organization completes whatever formal release activities are required by its processes. This gives teams the benefits of short feedback loops without pretending that every increment should immediately reach patients or clinicians. It is a hybrid idea, but that is not a weakness. Medical technology often needs hybrids. ## Human Factors Need Shorter Feedback Loops Too Software can satisfy its technical requirements and still create risk because people misunderstand it. Imagine an alert that is technically correct but visually similar to an informational notification. Or a configuration screen where two clinically different settings look nearly identical. Or a workflow requiring clinicians to remember information displayed three screens earlier. Those are not conventional coding defects. They can still matter enormously. Iterative development creates opportunities to put prototypes and working increments in front of representative users earlier. The earlier a team discovers that people interpret an interface incorrectly, the cheaper it is to reconsider the design. Waiting for a nearly finished product before evaluating real workflows wastes one of Agile's most valuable advantages. ## Where External Engineering Partners Enter the Picture Medical technology organizations frequently use external software engineers to increase capacity, add specialized expertise, or accelerate complex digital initiatives. That can work well. It can also create another boundary where information disappears. The dangerous version looks like this: The manufacturer owns requirements and compliance. The vendor owns code. Files travel between them occasionally. Each organization maintains its own definition of progress. That separation becomes painful during verification and release. A stronger partnership embeds engineering into the manufacturer's broader lifecycle. Companies such as **Zoolatech**, for example, can contribute software engineering capabilities to complex product environments where development needs to coordinate with architecture, quality, security, testing, and product stakeholders. For a medical device manufacturer choosing any engineering partner, though, headcount is not the most interesting question. Ask how the team actually works. Can developers operate within your lifecycle procedures? Can engineering artifacts remain traceable? How are design changes documented? How are risk-related requirements communicated? What happens when verification fails? How are third-party components controlled? Can the team support software after release? Can documentation evolve at the same pace as implementation? These questions expose whether a vendor is simply supplying programmers or participating in a controlled engineering system. ## What a Practical Agile Medical Device Process Looks Like The details vary dramatically between products, but the underlying flow can be surprisingly understandable. ### 1. Define the Product Before Optimizing the Sprint Clarify intended use, users, major system boundaries, clinical context, and essential product behavior. Agile helps teams manage uncertainty. It should not be used to avoid fundamental product decisions. ### 2. Establish the Initial Risk Baseline Identify important hazards and risk-control needs before detailed implementation begins. This baseline should evolve as the product evolves. ### 3. Create the Architectural Foundation Define major components, interfaces, data flows, safety boundaries, external dependencies, and security-sensitive areas. Do enough architecture to understand the dangerous unknowns. ### 4. Build a Traceable Backlog Translate requirements into manageable increments while preserving relationships to higher-level needs, risks, and verification activities. Not every backlog item needs to look like a consumer-app user story. Clarity matters more than Scrum purity. ### 5. Develop Small Pieces Small increments make code easier to review, test, understand, and change. They also reduce the amount of uncertainty introduced at once. ### 6. Verify During the Sprint Testing should accompany implementation wherever practical. Do not automatically postpone meaningful verification until the release is supposedly finished. ### 7. Update Risk and Documentation If the implementation changes something relevant, associated evidence should follow. The product and its documentation should describe the same reality. ### 8. Review More Than the Demo Sprint reviews are useful, but a polished interface is not proof of completion. Review verification status, anomalies, traceability, risk implications, and documentation where relevant. ### 9. Integrate Continuously Frequent integration exposes compatibility problems before they spread across months of development. ### 10. Release Deliberately Several increments may form one controlled release. Release decisions should consider the complete product state, not merely whether the sprint backlog is empty. ## The Metrics Need to Change Sprint velocity is attractive because it produces a number. Unfortunately, the number can be almost meaningless. A team might increase velocity by 30% while creating twice as many defects and accumulating substantial documentation debt. That is not acceleration. It is borrowing time from the future. Regulated software organizations need a more balanced view. Useful indicators might include: | Question | Possible Indicator | | ------------------------------ | ------------------------------------- | | Are defects being contained? | Defect escape rate | | Is verification keeping pace? | Verification completion rate | | Is the product traceable? | Trace coverage | | Is automation helping? | Regression automation coverage | | Is integration stable? | Build failure rate | | Are risks being addressed? | Open risk-control actions | | Is security debt accumulating? | Unresolved high-severity findings | | Is evidence falling behind? | Documentation completed per increment | | Are releases predictable? | Release lead time | Metrics should expose the health of the development system. They should not merely make a dashboard look busy. ## Three Versions of Agile That Usually Fail ### Feature-Factory Agile Everything is measured by the number of features delivered. Risk, architecture, verification, and documentation are viewed as overhead. Eventually the organization discovers that "90% finished" means something closer to 60%. ### Waterfall Wearing Scrum Clothing The organization runs daily stand-ups and two-week sprints, but requirements, testing, quality, and regulatory activities still happen in enormous sequential phases. The ceremonies are Agile. The information flow is not. ### Cowboy Agile Requirements are informal. Documentation is optional. Architecture changes without records. Testing depends heavily on individuals. Someone eventually says, "We'll clean everything up before submission." This is not Agile. It is unmanaged development. ## FAQ ### What is agile medical device software development? It is the application of iterative and incremental software-development practices within the controls required for medical device development. The approach combines short feedback loops with appropriate requirements management, risk management, verification, traceability, configuration control, and documentation. ### Does the FDA allow Agile development for medical device software? Agile practices can be used in regulated medical device development. Notably, FDA recognizes AAMI TIR45:2023, guidance specifically addressing Agile practices in medical device software development. ### Does IEC 62304 force companies to use Waterfall? No specific Waterfall, Agile, Scrum, or V-model methodology is mandated simply by IEC 62304; the important issue is satisfying the applicable lifecycle activities and maintaining the necessary evidence. ### Can Scrum be used for SaMD? Scrum practices can be part of a SaMD development approach, but Scrum alone does not provide a complete regulated lifecycle. Risk management, traceability, verification, configuration management, documentation, cybersecurity, and quality-system activities still need to be addressed. ### Should risk analysis happen in every sprint? The exact implementation depends on the product and quality system, but risk management should remain connected to changes throughout development rather than being treated solely as a one-time pre-release activity. ### What is the biggest mistake companies make when adopting Agile in MedTech? Separating "Agile development" from "compliance work." Once engineering and regulatory evidence run on different timelines, documentation debt and late surprises become increasingly likely. ## People Also Ask ### Is Agile better than Waterfall for medical devices? Neither methodology is automatically superior. Agile is particularly useful where teams face substantial uncertainty and benefit from frequent feedback. More sequential approaches may remain useful for certain hardware dependencies or stable development stages. Many organizations therefore adopt hybrid models. ### How do you maintain traceability in Agile? Requirements, risks, implementation artifacts, verification activities, and results should use persistent relationships or identifiers. Modern lifecycle-management tools can reduce the amount of manual synchronization required. ### Can medical device requirements change during development? Yes, but changes need to be controlled. Teams should understand their impact on architecture, risk controls, verification, documentation, and other affected lifecycle artifacts. ### How long should a medical device software sprint be? There is no universally correct sprint duration. Two-week iterations are common in software development, but cadence should support the organization's engineering and quality processes rather than becoming an objective by itself. ### Does every sprint need regulatory documentation? The better question is whether the evidence affected by the sprint remains current. If implementation changes a requirement, risk control, architecture decision, or verification activity, the corresponding records should not be allowed to drift indefinitely. ## The Quiet Advantage of Agile in MedTech Agile is often sold as a way to go faster. That description misses its most important benefit. Agile shortens the distance between a decision and evidence about whether that decision was good. A team creates a smaller increment. It tests it. Someone uses it. An assumption fails. The team learns. The design changes. That loop is powerful in any software company. It is especially valuable when discovering a bad assumption late can mean redesigning a safety-related system, repeating extensive verification, or delaying a regulated release. The goal of **[agile medical device software development](https://zoolatech.com/industries/healthcare/medical-device-software-development/)** should therefore not be maximum velocity. It should be minimum unmanaged uncertainty. That distinction changes how teams think about almost everything: sprint planning, architecture, testing, risk management, documentation, cybersecurity, and even outsourcing. Organizations working with engineering partners such as Zoolatech should expect the same discipline across organizational boundaries. External engineers cannot operate in one fast-moving universe while quality and regulatory teams operate in another. The product is one system. The evidence needs to describe that system. And the people building both need to work on roughly the same clock. That is the version of Agile worth pursuing in medical technology. Not Agile because two-week sprints sound modern. Not Agile because somebody wants a higher velocity chart. Agile because medical device development contains uncertainty, and uncertainty is safer when confronted early. The winning organization is not necessarily the one that writes code fastest. It is the one that can change direction without losing control of what changed, why it changed, how it was tested, and what that change means for the product as a whole.